Chronic Lymphocytic Leukemia U2-VEN-207 (ULTRA-V)

Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia

Back To Clinical Trials NCI Database Entry